New eczema drug 611 shows promise in large chinese trial
NCT ID NCT06173284
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tested a new drug called 611 in 519 Chinese adults with moderate-to-severe atopic dermatitis (eczema). 611 is an antibody that blocks a key driver of allergic inflammation. The study compared 611 injections to a placebo over 16 weeks, measuring skin clearance and severity scores. The trial is completed, and results will show if 611 can effectively reduce eczema symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
611 (a lab-made antibody that blocks a protein involved in allergic inflammation)
What this could lead to
If successful, 611 could offer a new treatment option for Chinese adults with moderate-to-severe eczema, helping to clear skin and reduce itch.
What could go wrong
This is a completed Phase 3 trial, but results are not yet published. As a biologic, it may have side effects like injection reactions or infections. It may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DERMATITIS, ATOPIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310003, China
-
Dermatology Hospital of Jiangxi Province
Nanchang, Jiangxi, 330200, China
-
Peking University People's Hospital
Beijing, Beijing Municipality, 100044, China
-
The Fourth Affiliated Hospital Zhejiang University School of Medicine
Jinhua, Zhejiang, 322000, China